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PTLD is a serious complication of iatrogenic immunosup-
pression, typically in the setting of solid organ trans-
plantation. For patients undergoing allogeneic stem cell
transplant. Potential risk factors include a T-cell depleted
graft, , HLA-mismatch, and GVHD.
Patients and Methods: We searched for PTLD occurrence
among 68 consecutive haplo-cord stem cell transplant re-
cipients treated at The University of Chicago in order to
describe its incidence, patient-, disease- and treatment-
related characteristics. Haplo-cord transplantation consisted
of a single cord blood unit augmented by a CD34+ selected
haploidentical G-CSF mobilized peripheral blood stem cell
graft from a related donor. Conditioning consisted of ﬂu-
darabine, melphalan and rabbit ATG. After the 3rd noted
PTLD, routine PCR monitoring of peripheral blood for EBV
was implemented.. Further evaluation for PTLD was as clin-
ically indicated, usually prompted by high EBV PCR copy
number with or without associated symptoms.
Results: 68 patients (med age 48 yrs, range 4-69) underwent
haplo-cord transplantation; 8 patients (11.8%) were subse-
quently diagnosed with PTLD based on either clinical (n¼3)
or pathologically-proven (n¼5) criteria. All haploidentical
donors for the 8 PTLD patients had positive EBV serologies.
The median age of these 8 patients was 39 yrs (range, 28-51).
The median time from transplantation to development of
PTLD was 103 days (range, 68-164d). Among 4 patients with
a pathologically-conﬁrmed diagnosis, morphology was EBV+
monomorphic DLBCL, while a 5th patient had ﬂow cytom-
etry-based diagnosis showing a monomorphic lambda
restricted B-PTLD. All patients with biopsy-proven PTLD
were also strongly CD30+ with diffuse staining pattern. In 3
patients, the diagnosis of PTLDwas based on rapid rise of EBV
titers along with new onset adenopathy. The median EBV
viral load peak of all patients with PTLD was 2.39 million
(range, 23,000 to 10 million). There were no differences in
age, gender, or proportionwith lymphoid or myeloid disease.
All patients were treated with reduction of immunosup-
pression plus rituximab; one patient with CNS lesions was
treatedwith R-CHOP x 4 plus intrathecal methotrexate and is
currently in remission. 3 pts have died, including 2 deaths
due to PTLD.
Summary: PTLD is a common complication following haplo-
cord transplantation, likely related to ATG treatment and
HLA mismatch in the cord blood setting. We advocate close
EBV surveillance and prompt rituximab treatment for this
approach. The observation that CD30 positivity is common
raises the possibility that brentuximab vedotin could be used
along with other standard approaches in management.349
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Chronic Graft versus Host Disease (CGVHD) is an autoim-
mune-like disorder that remains the main cause of non-
relapse morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (alloHSCT), yet its
pathogenic mechanisms remain poorly understood. To
identify the systemic cytokine pathways supporting the
development and persistence of CGVHD, we performed
microarray analysis on sorted monocytes from normal con-
trols (NC) and patients with severe cutaneous involvement,
including both lichenoid and sclerotic CGVHD. Monocytes
were chosen as in vivo reporter cells, capable of upregulating
distinct patterns of gene expression in response to different
cytokines. Two main pathways were determined to be
signiﬁcantly upregulated. (1) Interferon (IFN)-inducible
genes including those involved in signaling, anti-viral func-
tion, lymphocyte homeostasis and trafﬁcking, apoptosis and
antigen uptake and presentation (STAT1, GBP1, IL15,
TNFSF13B, CXCL10, TNFSF10, FCGR1A, MSR1, TAP1). (2) Upre-
gulation of innate immune TLR/RIG1/CLR receptors that can
respond to pathogens or cell damage by triggering IFN pro-
duction and inﬂammasome formation (TLR2, TLR4, AIM2,
DDX58, IFIH1, CLEC4E). Based on the microarray proﬁle, we
designed a multiplex RNA analysis probe set to test gene
expression in monocytes from (1) CGVHD patients with a
broad range of organ involvement, (2) alloHSCT patients
without clinical signs of CGVHD (NP) and (3) normal controls
(NC). The genes involved in IFN induced and innate immune
pathways that were identiﬁed by microarray analysis were
veriﬁed in this more quantitative analysis in 75 CGVHD, 14
NP and 20 NC; comparable upregulation of these pathways
was found in patients with extensive lichenoid or sclerotic
CGVHD. Furthermore, these pathways were substantiated in
ELISA assays by elevated levels of IFN induced chemokines
(CXCL9, CXCL10) and cytokines (BAFF) in CGVHD patient
plasma, and were consistent with increased levels of Type I
Interferon producing cells and IFN-induced factors (MXA,
CXCL9) in inﬂammatory inﬁltrates in CGVHD targeted tis-
sues. These results suggest that IFN induced by the innate
immune system’s response to damage associated molecular
patterns (DAMP) could initiate and contribute to a sustained
inﬂammatory process in CGVHD.350
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MDS/MPN are hematopoietic malignancies with both
dysplastic and proliferative features. Therapeutic options are
limited, with low probabilities and durations of remission.
Allogeneic HCT is the only potentially curative treatment;
however few data on outcomes and risk factors for survival
inMDS/MPN have been reported.We thus evaluated our HCT
experience with MDS/MPN.
MDS % MDS/MPN % sAML % P-value
Grade 2-4 aGVHD 44 55 42 0.75
Chronic GVHD 33 35 39 0.82
5-yr Relapse Mortality 22 33 43 0.28
5-yr NRM 44 33 42 0.67
5-yr OS 34 33 15 0.82
Table 1
Baseline Characteristics of 381 patients undergoing allogeneic HSCT
Characteristic HSCT Patients (N ¼ 381)
Age (years)
Median 53
Range 19-71
Gender
Male 58.3%
Race
Caucasian 94.0%
Primary malignancy
ALL 13.1%
AML 36.0%
MDS 18.6%
CLL 11.5%
CML 6.0%
Lymphoma 4.5%
Plasma-Cell-Disorders 7.9%
Non-Malignant-Disorders 2.4%
Graft type
Peripheral-Blood 86.9%
Bone-Marrow 10.5%
Umbilical-Cord-Blood 2.6%
Total body irradiation
Myeloablative 36.0%
Reduced Intensity/Nonmyeloablative 14.4%
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S227From 2000 to 2013, we retrospectively identiﬁed 142 pa-
tients who underwent HCT for MDS (n¼84), MDS/MPN
(n¼20) or secondary acute myeloid leukemia (sAML) (n¼38)
from a prior MDS or MDS/MPN, as deﬁned by WHO criteria.
Median age at transplant was 55 yrs (range 41-67) for MDS/
MPN, 52 yrs (20-70) for MDS and 56 yrs (29-73) for sAML.
Among MDS/MPN patients, 14 had CMML and 6 had MDS/
MPNunclassiﬁable, 2 of which evolved from anMPN. Prior to
HCT, 44% of MDS patients received hypomethylating agents
(HMA), 12% intensive chemotherapy (IC), and the remaining
other or no treatment. A minority received a combination of
therapy. Similarly, 40% of MDS/MPN patients received HMA,
15% IC, 20% no treatment and 30% additional treatment such
as hydrea or ruloxitinib. Most (79%) sAML patients received
IC. 36% MDS, 15% MDS/MPN and 34% sAML patients had in-
termediate or high (35%, 45%, 42%, respectively) comorbidity
scores. At time of HCT, 13% MDS, 20% MDS/MPN and 24%
sAML had >10% blasts. The majority (74% MDS, 65% MDS/
MPN, 66% sAML) received standard HCT with busulfan (Bu)/
cyclosphosphamide, and the remaining had reduced-in-
tensity HCT with ﬂudarabine (Flu)/total body irradiation or
Bu/Flu. All MDS/MPN patients had an HLAmatched related or
unrelated donor, with a minority of MDS (7%) and sAML
(16%) patients receiving cord blood.
There were no differences in time to hematopoietic recovery
or GVHD in all three disease groups. There was a higher
incidence of relapse at 5 yrs in sAML (47%) and MDS/MPN
(43%) compared to MDS (32%) however this was not signif-
icant. 100-day non-relapse mortality (NRM) was similar, 15%
MDS, 20%MDS/MPN and 13% sAML, andmost commonly due
to infection. Overall survival (OS) was worse in sAML
compared to MDS/MPN and MDS but not statistically sig-
niﬁcant (Table). Multivariable analysis identiﬁed intermedi-
ate/high risk comorbidity scores (HR 1.67, 95% CI 1.04-2.69,
p¼0.04) and blast count >10% (HR 1.69, 95% CI 1.02-2.81,
p¼0.04) as signiﬁcant risk factors for mortality. A blast count
of 5-10% (HR 1.01, 95% CI 0.6-1.7, p¼0.97) was not found to be
a signiﬁcant factor, along with diagnosis, IPSS score, cyto-
genetics, prior therapy, or conditioning regimen.
This analysis reinforces that HCT remains a valid treatment
option for patients with MDS/MPN. Relapse is still a major
cause of treatment failure and patients with high blast count
or comorbidity scores are unlikely to beneﬁt from HCT.351
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Rochester, MNBackground: Voriconazole (Vori) is a common antifungal
medication used in allogeneic hematopoietic stem cell
transplantation (allo-HSCT) patients. In solid organ trans-
plantation, multiple studies have associated the use of vori
with the development of squamous cell carcinoma (SCC)
post-transplant, but its association with SCC in allo-HSCT
patients is unknown.
Methods: Mayo Clinic’s transplant database (2007-2012)
was accessed and electronic charts of allo-HSCT patients
were reviewed. Vori exposure was deﬁned as its exposure at
any time during treatment of primary disease, prior to or
following HSCT. Cumulative vori exposure was deﬁned as
total days of voric use following HSCT; days were not
required to be consecutive. Two time-dependent vori expo-
sure variables were deﬁned: (1) history of vori exposure (yes/
no) over time, and (2) cumulative days on vori over time.
Results: 404 patients underwent allo-HSCT during this
timeframe, and 381 patients (table 1) were included in the
ﬁnal analysis. 312/381 received vori; other antifungal
therapy included ﬂuconazole (n¼40), posaconazole (n¼23),
anidulafungin (n¼1), and caspofungin (n¼5). Median
